Zentiva Romania increased its production capacity by 12.5 percent in 2018 compared to 2017, which allowed the pharmaceutical producer to sell 973 million units last year. Sales revenues declined slightly from RON 46.8 million in 2017 to RON 425.8 million.
Last year, the company registered a consolidated turnover of RON 461.4 million and a profit of RON 262.6 million. Zentiva SA’s profit in 2018 includes some non-recurring items, both in terms of costs and revenues, which resulted from its separation from Sanofi. For this reason, the profit for 2018 was significantly higher than that obtained in 2017.
In 2018, Zentiva allocated RON 20 million to invest in new equipment and upgrade existing capacities. The funds were mainly allocated to the solid and packaging production area. The company also invested RON 7.72 million in research and development processes that allowed it to start local production for 10 new products for external markets. Over 50 percent of production goes to countries such as Germany, Great Britain, France, Italy, Switzerland, the Czech Republic and others.
“Zentiva is a major player in the generic market. We are making a significant contribution to the healthcare system by providing effective and affordable treatments that reduce the pressure on public resources allocated to medicines. By virtue of this role, we want to continue to have a dialogue with the authorities on solutions to enable local generic manufacturers to increase access to healthcare, to invest locally and to support communities economically,” said Simona Cocos, general manager of Zentiva Romania.
Zentiva Romania is the market leader in generic medicines with a market share of 16.1 percent and an annual increase of 6.3 percent between March 2018 and February 2019. The main therapeutic areas in which Zentiva is one of the major players in the market are cardiology, gastroenterology, urology and nervous system.